Related references
Note: Only part of the references are listed.Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine
Ho Sze Chan et al.
EJNMMI RESEARCH (2016)
Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate
Ho Sze Chan et al.
EJNMMI RESEARCH (2016)
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
C. Kratochwil et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
The Advantage of Antibody Cocktails for Targeted Alpha Therapy Depends on Specific Activity
Jordan B. Pasternack et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
MIRD Pamphlet No. 25: MIRDcell V2.0 Software Tool for Dosimetric Analysis of Biologic Response of Multicellular Populations
Behrooz Vaziri et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy
Franziska Graf et al.
PLOS ONE (2014)
Somatostatin Analogues for Receptor Targeted Photodynamic Therapy
Slavka Kascakova et al.
PLOS ONE (2014)
Redefining Relative Biological Effectiveness in the Context of the EQDX Formalism: Implications for Alpha-Particle Emitter Therapy
Robert F. Hobbs et al.
RADIATION RESEARCH (2014)
The potential and hurdles of targeted alpha therapy - clinical trials and beyond
Jorgen Eigqvist et al.
FRONTIERS IN ONCOLOGY (2014)
Iodination and Stability of Somatostatin Analogues: Comparison of Iodination Techniques. A Practical Overview
Erik de Blois et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)
Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody
Hong Song et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Microdosimetry for Targeted Alpha Therapy of Cancer
Chen-Yu Huang et al.
COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE (2012)
Bismuth-213 and Actinium-225 - Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Alfred Morgenstern et al.
CURRENT RADIOPHARMACEUTICALS (2012)
Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides
Erik de Blois et al.
APPLIED RADIATION AND ISOTOPES (2011)
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
George Sgouros et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry-Standardization of Nomenclature
Wesley E. Bolch et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Cross-fire doses from β-emitting radionuclides in targeted radiotherapy.: A theoretical study based on experimentally measured tumor characteristics
S. A. Enger et al.
PHYSICS IN MEDICINE AND BIOLOGY (2008)
Somatostatin-receptor-targeted α-emitting 213Bi is therapeutically more effective than β-emitting 177Lu in human pancreatic adenocarcinoma cells
Tapan K. Nayak et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
Counting colonies of clonogenic assays by using densitometric software
Maximilian Niyazi et al.
RADIATION ONCOLOGY (2007)
213Bi-[DOTA0,Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model
JP Norenberg et al.
CLINICAL CANCER RESEARCH (2006)
Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy
B Bernard et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948
S Verwijnen et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
Share Paper
